Utebzi (tebipenem pivoxil)
GlaxoSmithKline (GSK)
ApprovedJun 17, 2026
Marketer take
The first oral carbapenem in the US, for cUTI patients with limited oral options, which opens a discharge and outpatient message, tempered by antibiotic stewardship controls.
- Sponsor company
- GlaxoSmithKline (GSK)
- Indication
- To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options
- Therapeutic area
- Infectious disease
- Event
- FDA approval
- Date
- Jun 17, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?